This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

9 May 2011

Merck & Teva Near Settlement Over Vytorin

Merck and Teva are close to settling patent disputes over a generic version of the cholesterol drug Vytorin.

Merck & Co. is close to settling patent lawsuits against Teva Pharmaceutical Industries Ltd. over a generic version of the cholesterol drug Vytorin, court documents show.


The company and its would-be generic rival Teva requested time to "finalize settlement" of two patent lawsuits now pending in a New Jersey court.


After Teva filed for FDA approval for its copycat form of Vytorin in March of last year, Merck sued the generics giant, citing patents that are set to expire in 2014 and 2017. Merck spokesman Ron Rogers

Related News